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Background: To evaluate the relationship between bone loss and new bone formation in ankylosing spondylitis
(AS) using 10-year X-ray, dual-energy x-ray absorptiometry (DXA) and quantitative computed tomography (QCT)
follow-up.
Methods: Fifteen AS patients free from medical conditions and drugs affecting bone metabolism underwent X-ray,
DXA and QCT in 1999 and 2009.
Results: In spine QCT a statistically significant (p = 0,001) decrease of trabecular bone mineral content (BMC) was
observed (change ± SD: 18.0 ± 7.3 mg/cm
3). In contrast, spine DXA revealed a significant increase of bone mineral
density (change ± SD: -0.15 ± 0.14 g/cm
2). The mean BMC, both at baseline and follow-up was significantly lower
(p = 0.02 and p = 0.005, respectively) in advanced radiological group as compared to early radiological group.
However, in multiple regression model after adjustment for baseline BMC, the baseline radiological scoring did not
influence the progression of bone loss as assessed with QCT (p = 0.22, p for BMC*X-ray syndesmophyte scoring
interaction = 0.65, p for ANOVA-based X-ray syndesmophyte scoring*time interaction = 0.39). Baseline BMC was
the only significant determinant of 10-year BMC change, to date the longest QCT follow-up data in AS.
Conclusions: In AS patients who were not using antiosteoporotic therapy spine trabecular bone density evaluated
by QCT decreased over 10-year follow-up and was not related to baseline radiological severity of spine
involvement.
Background
Osteoporosis is a well recognized early feature of anky-
losing spondylitis (AS) particularly pronounced in active
disease [1,2]. In AS axial osteoporosis coexists with new
bone formation, ie. syndesmophytes, spine ligaments
ossification and facet joints ankylosis, thus the outer
layer of the spine is hipermineralized (Figure 1A) as
opposed to bone density within vertebral bodies which
is diminished. In the effect the risk of vertebral fractures
increases [3,4].
Bone density in AS is assessed by dual-energy x-ray
absorptiometry (DXA) and quantitative computed tomo-
graphy (QCT). The DXA measures areal bone mineral
density (BMD, g/cm
2). Spine anteroposterior DXA reli-
ably detects osteoporosis in early cases but in advanced
AS it overestimates BMD due to new bone formation.
Spine QCT facilitates measurement of volumetric trabe-
cular bone mineral content (BMC, mg/cm
3)w i t hn o
cortical bone and “outer layer” artifacts. The discrepancy
between DXA and QCT in AS is marked in advanced
disease, where the majority of patients have normal
DXA BMD but QCT shows trabecular bone loss [5].
AS patients with more pronounced new bone forma-
tion are at greater risk of osteoporosis [6]. However, to-
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serious complication.
Therefore the objective of this study was to evaluate
the relationship between bone loss and new bone forma-




In 1999 thirty seven males fulfilling New York modified
AS criteria, with no concomitant diseases and drugs
affecting bone metabolism, underwent X-ray (spine),
DXA (spine and hip) and QCT (spine) measurements
[7]. In 2009 fifteen patients underwent X-ray, DXA and
QCT. Of the 22 excluded patients, 14 were treated with
bisphosphonates and/or corticosteroids, 3 refused to
participate, 1 lost contact. Three patients died. In one
patient QCT was not feasible due to unsatisfied
positioning.
2. Imaging and bone density
We obtained standard radiographs of the lumbar and
thoracic spine at baseline and follow-up.
DXA was performed at L2-L4 and left hip using Lunar
DPX-IQ (1999) and Lunar Prodigy (2009, Lunar, USA).
Right hip was scanned if the left was difficult to position
or hip replacement had been performed. In one patient
with new L2 and L4 fractures L3 was analyzed. The
coefficient of variation (CV) for repeated measurements
in vivo and least significant change at 95% confidence
level (spine) were 2,2% and 0,062 g/cm
2 for DPX-IQ
and 1,6% and 0,043 g/cm
2 for Prodigy, respectively. T-
scores and g/cm
2 were based on manufacturer-supplied
reference values.
QCT (L1-L5) was determined at baseline and follow-
up with single-energy QCT (Twin Flash, Marconi,
USA). Standard calibration phantom (Picker) recom-
mended by Marconi was used for each scan. First, from
the lateral lumbar spine scannogram the midportions of
L1-L5 vertebral bodies parallel to the endplates were
localized manually. Then, scans of 10 mm thickness
were carried out in each vertebrae and other scanning
parameters were set according to scanner manufacturer.
Data from scanning elliptical region of interest (ROI,
Figure 1B) including only trabecular bone, was analyzed
using software CirsCT Bone Densitometry of CIRS
A B
A B
Figure 1 (A) Anteroposterior lumbar radiograph with advanced syndesmophytes and (B) Quantitative Computed Tomography scan of
L5 vertebral body showing elliptical region of interest (ROI) containing trabecular bone (48-year-old patient at baseline).
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were calculated using manufacturer’s reference data.
The fractured vertebrae were excluded from analyses.
3. Statistical analysis
We compared means using t-test and proportions using
chi-square test, where applicable. To check the prognostic
value of studied variables on follow-up BMC, we fitted
multiple regression models, both without and after adjust-
ment for baseline values of age, body mass index (BMI),
erythrocyte sedimentation rate (ESR), smoking, QCT
derived BMC stratum, radiologic score and duration of dis-
ease prior to baseline visit. To enable visual inspection of
individual patient data, we plotted the baseline and follow-
up values of measures of bone-density in strata of baseline
BMC based on QCT. To formally test the between-subject
(BMC baseline strata) differences in studied variables, we
fitted the two-way ANOVA models. Finally, using linear
regression approach, we assessed interaction between BMC
and radiographic scoring at baseline, in their influence on
measures of bone density at follow-up.
Results
1. Patient characteristic
Mean ± SD baseline age of 15 included patients was
45.6 (± 7.3) years and disease duration averaged 16.5 (±
8.6) years. ESR averaged 41.8 mm/hr (± 27.5), BMI 27.4
(± 4.2), 33,3% patients were smoking. Three patients
experienced four new vertebral fractures during follow-
up (Th7, Th12, L2, L4). Baseline and follow-up densito-
metry results are shown in table 1.
2. Relationship between QCT and DXA results
We used stratification of patients based on baseline QCT
according to Kalender et al. [8](normal >120; osteopenia
80–120; osteoporosis < 80; mg/cm
3) to follow changes in
QCT and DXA. In QCT at baseline there were 4 patients
in normal stratum, 5 had osteopenia and 6 osteoporosis.
To follow changing bone density data were plotted for
individual patients (Figure 2). In spine QCT a statistically
significant (p = 0,001) decrease of bone density (change ±
SD: 18.0 ± 7.3) was observed, and it was universal across
all strata (Figure 2). There were no clear-cut trends
across strata in DXA that would resemble those noted in
spine QCT. In spine DXA, a significant BMD change was
noted (p = 0,0009) with trend towards increased density
(change ± SD: -0.15 ± 0.14). Neither neck nor Ward
DXA changed from baseline to follow-up. There was no
correlation between QCT and DXA, both in density units
and T- scores - at baseline and follow-up. Additionally, to
test the between-subject (BMC baseline strata) differ-
ences in studied variables, we fitted the two-way
ANOVA models. We found that the baseline stratifica-
tion by BMC significantly influenced the BMC values
both at baseline (p < 0.0001) and at follow-up (p =
0.0009), but had no impact on the indices derived from
DXA (all p > 0.07). We found no interaction between
baseline BMC stratum and time-related change in all stu-
died variables (all p > 0.31).
3. Relationship between QCT and new bone formation
To determine the effect of radiological severity on
BMD/BMC change X-rays were assessed and patients
were split into two groups based on baseline syndesmo-
phyte scores according to Devogelaer [9] (table
embedded in Figure 3); early group (grade 0-I, ie. no
definite syndesmophytes) - 7 patients; and advanced
group (grade II-IV, ie. bridging syndesmophytes) - 8
patients (Figure 3). At follow-up 6 patients progressed
into advanced group.
Table 1 Mean DXA and QCT results at baseline and at follow-up
baseline follow-up change p
absolute T-score absolute T-score
QCT L1-L5, mean (mg/cm
3) 94.2 -3.654 76.1 -4.468 18.0 0.001*
(SD) 31.8 1.246 33.5 1.499
median (25th-75
th percentile) 96.5 (68.2-122.5) 77.5 (47.0-113.7)
DXA L2–L4, mean (g/cm
2) 1.027 -1.780 1.180 -0.493 -0.15 0.0009*
(SD) 0.183 1.531 0.198 1.649
median (25th-75
th percentile) 0.96 (0.86-1.24) 1.19 (1.0-1.35)
DXA neck, mean (g/cm
2) 0.892 -1.131 0.926 -1.108 -0.03 0.48
(SD) 0.134 1.077 0.279 2.139
median (25th-75
th percentile) 0.86 (0.83-0.92) 0.88 (0.83-0.96)
DXA Wards, mean (g/cm
2) 0.737 -1.715 0.727 -1.792 0.01 0.81
(SD) 0.129 0.992 0.231 1.776
median (25th-75
th percentile) 0.73 (0.65-0.82) 0.69 (0.62-0.79)
DXA, dual-energy x-ray absorptiometry; QCT, quantitative computed tomography.
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Page 3 of 7Figure 2 Measures of bone density at baseline and after 10-year follow-up in 15 patients in four regions of interest: L1-L5 (QCT), L2-
L4 (DXA), neck (DXA) and Wards (DXA) with regard to BMC baseline stratification. Each baseline BMC stratum is represented by different
colors: black (normal), green (osteopenia), red (osteoporosis).
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significantly lower (p = 0.02 and p = 0.005, respectively)
in advanced group (77.2 ± 21.5 and 55.4 ± 18.9 mg/cm
3,
baseline and follow-up, respectively) as compared to
early group (113.6 ± 31.7 and 99.8 ± 31.1 mg/cm
3, base-
line and follow-up, respectively).
However, in multiple regression model after adjust-
ment for baseline BMC, the baseline radiological scoring
did not influence the progression of bone loss as
assessed with QCT (p = 0.22, p for BMC*X-ray syndes-
mophyte scoring interaction = 0.65, p for ANOVA-
based X-ray syndesmophyte scoring*time interaction =
0.39).
To discover the predictive value of other variables
possibly influencing 10-year changes in BMC similar
multiple regression model was used. Only baseline QCT
values (mg/cm
3) predicted 10-year decrease in QCT;
with no influence of baseline DXA values, disease dura-
tion, age, ESR, smoking and BMI.
Discussion
We showed that in patients with ankylosing spondylitis
who were free from medical conditions and drugs affect-
ing bone metabolism, spine trabecular bone density
evaluated by QCT decreased over 10-year follow-up.
Despite of lower BMC in patients with more advanced
radiology scoring, the 10-year change was not related to
baseline radiological severity of spine involvement.
Study population was highly homogeneous and
included men with no history of steroid or bisphospho-
nate use over 10-year follow-up. The baseline syndesmo-
phyte formation was equally distributed between early
and advanced disease. Thus we have had a group of
early new bone formation, ie. scores 0–I corresponding
to lack or mild syndesmophyte formation and advanced
new bone formation, ie. scores II–IV corresponding to
severe bridging osteoproliferation. The higher radiology
scores in Devogelaer grading (Figure 3) the more pro-
nounced redistribution of bone, ie. loss of vertebral
bodies trabecular bone density is accompanied by an
increase in density of the outer layer of spine. This phe-
nomenon seems to be responsible for higher vertebral
fracture risk in AS since the osteoporosis within verteb-
ral bodies associated with increased rigidity of spine
makes it more vulnerable to fractures. The evolution of
these two contrary processes in the natural history of
AS is responsible for axial not peripheral fractures
[10,11]. There is an evidence that different bone density
measurements, including spine QCT showed similar
percentage differences (range 16–22%) between subjects
with vertebral fractures and controls [12-14] but in AS
these differences have not been examined yet.
We showed that QCT is a reliable technique and
spine a correct region to follow-up long term changes in
BMC, reflecting natural history of osteoporosis in anky-
losing spondylitis (Figure 2). Decline in BMC was statis-
tically significant and neither DXA of spine nor femoral
neck or Wards revealed a similar trend. In our group,
one patient showed an outlying increase in neck and
Ward’s values (Figure 2). After exclusion of this indivi-
dual the p value for change in DXA neck measurement
did not change (p = 0.80). However we observed a small
yet statistically significant (p = 0.02) decrease in DXA
measurement of Ward’s triangle which represents trabe-
cular bone and is compatible with our QCT findings.
This observation strengthens the possible impact of our
Figure 3 Radiographic grading at baseline and follow-up according to Devogelaer [9]. Digits represent number of patients in each grade
at baseline and follow-up. Thickness of lines is proportional to numbers of patients. Embodied is a Devogelaer X-ray grading.
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(either QCT or DXA Ward’s triangle) should replace
integral measurement of cortical and trabecular bone
(DXA neck or spine) in assessment of AS patients.
In addition, regression analysis determined that the
only one significant predictor of the final BMC was
baseline BMC. Lee did not show significant changes in
BMC over 15-month period, to date the longest pub-
lished study with QCT in AS [15]. They followed 14
patients; 7 with sacroiliitis alone (early AS) and 7 with
extensive vertebral syndesmophytes (late AS) thus with
number and strata resembling our group.
Our results suggest that baseline syndesmophytes
score has impact on trabecular bone density as early
and advanced groups differ regarding QCT values at
baseline and follow-up. Karberg using QCT and DXA
reported that greater bone loss is detected more fre-
quently in patients with syndesmophytes [6] and our
results confirm this as mean BMC in our advanced
group was in osteoporosis range both at baseline and at
follow-up. In contrast mean BMC in early group was
within osteopenia range, both at baseline and follow-up.
Although early and advanced groups differ in QCT
values, the baseline radiological severity had no predic-
tive value for bone loss over 10 years. It thus seems
likely that in ankylosing spondylitis bone loss does not
parallel new bone formation, contrary to findings by
Karberg et al. [6].
Our study has to be considered within context of its
limitations. The sample-size is relatively low, which
restricted our use of statistical techniques to disentangle
the effect of possible confounders. The NSAIDs treat-
ment, both continuous and on demand, may have influ-
enced syndesmophyte growth. It is hard to separate the
influence of disease and aging on trabecular bone density
as well. However, ours is longest follow-up data available
in a highly homogenous group of patients. Despite of the
relatively small group, we had > 80% power to detect 20%
difference in the BMC from baseline to follow-up, with
the 5% significance. On the other hand, we are aware,
that due to moderately-sized sample size the results we
obtained must be considered with caution.
Intriguing question is whether there is a link between
bone resorption and new bone formation in AS or
whether inflammation triggers both processes. Bone loss
is already seen in early AS and is due to disturbed bone
turnover rather than immobility caused by syndesmo-
phytes [6,9,15-17]. Markers of bone resorption were
found to be positively correlated with ESR and CRP
[18-20]. TNF blockade decreased inflammation in AS
and increased BMD [21], observations which link
inflammation with bone resorption.
Interaction between new bone formation and inflam-
mation in AS is not clear. Osteocalcin was found to be
decreased [22], normal [15,20] or increased [23] in AS
a n dw a su n r e l a t e dt ol e v e l so fi n f l a m m a t o r ym a r k e r s .
Most syndesmophytes are not associated with inflamma-
tion as based on MRI studies [24]. Anti-TNF treatment
in spondyloarthritis increased bone-specific alkaline
phosphatase (BALP) and negative correlation between
BALP and metalloproteinase-3 (bone destruction mar-
ker) was discovered, indicating that new bone formation
in AS occurs if inflammation is depressed [25]. Thus it
seems likely that bone loss and new bone formation in
AS are not directly linked with inflammation, and
according to our data they are not coupled - a hypoth-
esis which requires further studies.
Conclusions
In AS patients who were not using antiosteoporotic
therapy spine trabecular bone density evaluated by QCT
decreased over 10-year follow-up and was not related to
baseline radiological severity of spine involvement.
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